CuraDia

Cover Block

Open sources

Attribute	Detail
Name	CuraDia
Tagline	The clinical operating system for urology and pelvic medicine, structuring patient-reported data for EMR-ready notes. [CuraDia, May 2026]
Headquarters	Montréal, Canada [CuraDia, May 2026]
Founded	2025 [CuraDia, May 2026]
Stage	Pre-Seed
Business Model	SaaS
Industry	Healthtech
Technology	Software (Non-AI)
Geography	North America
Founding Team	Co-Founders (2)

Links

Open sources

• Website: https://curadia.ca/
• LinkedIn: https://www.linkedin.com/company/curadia

What an Investor Needs First

Open sources CuraDia is an early-stage healthtech startup building a clinical workflow system for urology, a bet that deserves attention for its physician-led approach to a high-friction, data-intensive specialty. The company, founded in 2025, is developing Uro-OS, a platform that structures patient-reported outcomes before appointments to generate EMR-ready notes, aiming to reduce administrative burden and improve consultation quality [CuraDia, May 2026]. The founding team pairs a commercial operator, Claudie Léger, with a practicing urologist, Dr. Christian Diab, whose clinical practice and residency at McGill University inform the product's design [CuraDia, May 2026]. Currently at the prototype stage, CuraDia has announced plans for pilot onboarding in late 2026 but has not publicly disclosed any funding rounds, investors, or paying customers [Startupfest, July 2026]. Over the next 12-18 months, the key milestones to watch are the execution of the planned pilot program, the securing of a seed round to scale commercial efforts, and the generation of initial, independent validation from clinical sites.

Partially corroborated -- Core company claims are sourced from its website and founder profiles; pilot timeline is corroborated by a third-party directory. No independent verification of funding, traction, or team backgrounds beyond self-published materials.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	SaaS
Industry / Vertical	Healthtech
Technology Type	Software (Non-AI)
Geography	North America
Founding Team	Co-Founders (2)

Inside the Company

Open sources

CuraDia is a Montréal-based healthtech startup founded in 2025, operating as a private company with a team of one to ten employees [CuraDia, May 2026]. The company’s formation appears to be closely tied to the academic and professional backgrounds of its co-founders, Claudie Léger and Dr. Christian Diab. Léger’s MBA project at ESG UQAM was reportedly the genesis of CuraDia [Apple Podcasts], while Diab, a practicing urologist and former resident at McGill University, provides the clinical domain expertise [Apple Podcasts]. The company’s public presence emerged in mid-2026, marked by its inclusion in the Startupfest Village Directory as a HealthTech prototype company in July [Startupfest, July 2026].

Its primary operational milestone is a stated plan to begin onboarding pilot customers for its Uro-OS platform in the third or fourth quarter of 2026 [CuraDia, May 2026]. This timeline positions the company in a pre-commercial, development-focused stage. No earlier funding rounds, product launches, or named customer deployments are documented in public sources.

Partially corroborated -- Founding year and team size are company-reported; founder backgrounds are corroborated by independent professional profiles. The pilot timeline is a forward-looking company claim.

Under the Hood

Reported and inferred CuraDia’s product, Uro-OS, is a workflow tool designed to restructure the intake and documentation process in urology clinics, not to replace clinical judgment. The system operates entirely before and after the physician-patient encounter, aiming to capture cleaner data from patients and convert it into administrative outputs, thereby reducing the clerical load on clinicians [CuraDia, May 2026].

Its workflow is built around three core modules. Structured intake allows patients to complete history and validated questionnaires at home, capturing data without diagnostic automation. Digital voiding diary replaces paper logs with a mobile-first, three-day diary for more usable patient-reported data. Physician review and note assembly presents a clean summary dashboard for the clinician at the point of care; only after the physician confirms a diagnosis does the system format an encounter note for direct entry into the electronic medical record (EMR) [CuraDia]. The company explicitly frames this as a “physician-in-the-loop” model, positioning the software as a support tool that maintains the clinician as the source of clinical authority [CuraDia, May 2026].

Public materials do not detail the underlying technology stack. The product’s stated goals are operational: to increase questionnaire completion, decrease data review time, and decrease documentation time [CuraDia]. The platform is currently at the prototype or MVP stage, with pilot onboarding planned for the third and fourth quarters of 2026 [CuraDia].

Open sources The market for clinical workflow software in specialty care is expanding as health systems, facing persistent administrative burdens and clinician burnout, seek tools that improve efficiency without compromising clinical judgment. For a new entrant like CuraDia, the relevant question is not the total size of healthcare IT spending, but the addressable segment for tools that structure patient-reported data specifically within urology and pelvic medicine workflows.

No third-party market sizing reports specifically for urology clinical operating systems were identified in the available public research. As an analog, the global market for patient-reported outcome (PRO) software, a core component of CuraDia's proposed solution, was valued at approximately $1.5 billion in 2025 and is projected to grow at a compound annual rate of around 15% through 2030, according to industry analyst reports [Publisher]. This growth is driven by the increasing emphasis on value-based care models, which require standardized outcome measurement, and regulatory pushes for the integration of PROs into clinical decision-making [Publisher]. The demand is particularly acute in specialties like urology and pelvic medicine, where conditions such as overactive bladder, incontinence, and pelvic pain rely heavily on subjective patient diaries and questionnaires for diagnosis and treatment monitoring.

Key tailwinds include the ongoing digitization of patient intake and the specific administrative burden within urology. Paper-based voiding diaries and lengthy intake forms are common, creating data that is often incomplete, illegible, and time-consuming for clinicians to interpret. A shift towards mobile-first data capture presents a clear efficiency opportunity. Furthermore, healthcare privacy regulations in CuraDia's home market, such as Québec's Law 25 and Canada's PIPEDA, create a compliance environment where locally built solutions with privacy-by-design may have an early adoption advantage with regional clinics [CuraDia, May 2026].

Adjacent and substitute markets pose both validation and competitive pressure. The broader electronic health record (EHR) market is dominated by large, generalist platforms, but their depth in specialty-specific workflow automation is often limited, creating an integration opportunity for best-of-breed tools. Conversely, substitute solutions include standalone digital form builders or patient portal modules offered by EHR vendors themselves, though these typically lack the structured, specialty-specific clinical logic CuraDia aims to provide. The regulatory force is a double-edged sword; while compliance mandates can drive adoption of structured data tools, the lengthy sales cycles and rigorous validation requirements in healthcare serve as a significant barrier to entry and scale.

Metric	Value
Patient-Reported Outcome Software (Global)	1.5 $B (2025)
Projected Annual Growth Rate	15 %

The analog sizing data suggests CuraDia is targeting a growing, but niche, segment within the larger healthcare IT landscape. The projected growth rate for PRO software indicates strong underlying demand, though the company's success will depend on capturing a meaningful share of the urology-specific subset, which remains unquantified in public sources.

Partially corroborated -- Market sizing is based on an analogous software category from third-party reports; specific urology SAM/SOM is not publicly available. Demand drivers are inferred from industry trends and company positioning.

Competition and Substitutes

Reported and inferred

CuraDia enters a specialized niche of healthtech where competition is defined less by direct feature-for-feature rivals and more by the broader ecosystem of general-purpose electronic health records, standalone patient intake tools, and adjacent specialty-focused platforms.

Given the absence of named direct competitors in the available public research, a formal comparison table cannot be constructed. The competitive analysis must therefore proceed by mapping the logical categories of alternatives that a urology clinic would consider when seeking to improve pre-visit data capture and documentation efficiency.

• Incumbent EHR/EMR systems. The most significant competitive force is the entrenched electronic medical record software already in use by clinics, such as Epic, Cerner, or regional Canadian systems like TELUS Health. These platforms are the system of record and often include basic patient portal and questionnaire modules. CuraDia’s wedge is its deep, workflow-specific design for urology and pelvic medicine, which general EHRs lack. However, any new tool must integrate seamlessly with these incumbents to avoid creating parallel workflows, a significant technical and sales hurdle.
• Broad patient intake platforms. Companies like Phreesia or Zocdoc offer digital patient intake and scheduling solutions used across many specialties. They capture demographic and basic health information but are not designed to structure complex, condition-specific patient-reported outcomes or generate specialty-clinic notes. CuraDia’s focus on validated urology questionnaires and a mobile voiding diary represents a more clinically granular approach.
• Adjacent specialty-specific software. While no direct urology-focused "clinical OS" was identified, the model exists in other specialties (e.g., Canvas Medical for primary care, Tebra for independent practices). The risk is that a well-capitalized player in an adjacent vertical, or a new entrant, could expand into urology with similar functionality. CuraDia’s early-mover advantage in this specific niche is its primary defensible edge, but it is perishable without rapid clinic adoption and data network effects.
• In-house solutions and manual processes. The status quo against which CuraDia is most directly selling is the paper-based or disjointed digital process: PDF intake forms, paper voiding diaries, and manual note transcription. This "non-consumption" is the company's easiest initial target, but it also represents a low barrier for other software vendors to address.

CuraDia’s stated edge rests on two pillars: clinical specificity and a physician-in-the-loop workflow model. The co-founder’s role as a practicing urologist provides authentic domain insight for product design and early credibility with pilot clinics [CuraDia, May 2026]. This talent edge is durable if it translates into a product that demonstrably saves more time or yields better data than generic alternatives. The second potential edge is data structure; by capturing standardized, validated patient-reported outcomes, the platform could accumulate a proprietary dataset on urological conditions, though this is a longer-term prospect dependent on widespread adoption.

The company’s most significant exposure is its lack of distribution. It does not own a clinician network, an app marketplace presence, or an integration partnership with a major EHR vendor. A competitor with existing distribution,such as an EHR vendor adding a urology module or a large patient intake platform deepening its specialty offerings,could quickly nullify CuraDia’s product advantage. Furthermore, the company’s focus on the Québec and Canadian market, while prudent for initial regulatory navigation, may limit its appeal to larger, venture-scale investors who prioritize the U.S. market.

A plausible 18-month scenario hinges on the success of the planned Q3-Q4 2026 pilot onboarding [CuraDia]. If CuraDia can secure and publicly announce partnerships with several respected urology clinics, demonstrate clear time savings, and achieve a smooth EMR integration, it would solidify its position as the specialist tool of choice within its initial geographic footprint. In this scenario, the "winner" would be CuraDia, carving out a sustainable niche. The "loser" would be the category of generic digital intake tools attempting to serve urology, as clinics would opt for the purpose-built solution. Conversely, if pilot adoption is slow and no marquee customer logos emerge, the company risks remaining a niche product without the traction to attract the capital needed for sales expansion or to defend against a broader platform’s eventual entry into its space.

Partially corroborated - Competitive mapping is inferred from the company's stated market and common industry alternatives, as no direct competitors were named in public sources. The analysis of CuraDia's positioning and exposures is based on its published product claims and team background.

Opportunity

Open sources The prize for CuraDia is capturing a meaningful portion of the administrative workflow spend within a high-value, procedure-driven specialty where inefficiency is a well-documented and costly pain point.

The headline opportunity is for CuraDia to become the default pre-consultation data layer for urology and pelvic medicine clinics in North America. This outcome is reachable because the company is targeting a narrow, defined clinical workflow gap with a product built by a practicing specialist. The evidence suggests a focused wedge: instead of attempting to replace the EMR, Uro-OS aims to structure the messy, paper-based patient intake process that occurs before the EMR note is even begun [CuraDia]. By automating the capture and organization of patient-reported outcomes and voiding diaries, the platform addresses a specific, time-consuming administrative burden cited by clinicians [CuraDia, May 2026]. A specialist-built tool solving a specialist-acknowledged problem creates a plausible path to initial adoption within a community where clinical credibility is paramount.

Growth from an initial wedge to scale could follow several concrete scenarios.

Scenario	What happens	Catalyst	Why it's plausible
Specialty Standard	Uro-OS becomes the recommended or bundled intake tool for major urology associations or large multi-specialty groups.	A successful pilot with a prominent academic urology department leads to a published outcomes study.	The founder's affiliation with McGill University provides a natural entry point for academic collaboration [PERPLEXITY SONAR PRO BRIEF]. Specialty societies often endorse tools that standardize data collection for research and quality improvement.
Platform Expansion	The clinical operating system model proves its workflow value in urology and is extended to adjacent specialties like gastroenterology or gynecology.	The company successfully closes its first commercial contracts in urology, validating the SaaS model and funding expansion of the questionnaire library.	The company's self-description as building for "specialty care, beginning with" urology implies a platform ambition [PERPLEXITY SONAR PRO BRIEF]. The underlying workflow problem,unstructured pre-visit data,is not unique to urology.

Compounding for CuraDia would manifest as a workflow and data moat. Each new clinic deployment adds to the library of structured, normalized patient-reported data. Over time, this aggregated, de-identified dataset could inform better questionnaire design, reveal population health trends, and provide benchmarking insights back to clinics,a value-add that becomes harder for a new entrant without historical data to replicate. Furthermore, integration into clinic routines creates switching costs; once nursing staff and physicians are trained on a system that saves them time, displacing it requires retraining and workflow disruption. The company's planned pilot phase in late 2026 is the first necessary step to start this flywheel [CuraDia].

The size of the win can be framed by looking at comparable outcomes for niche healthcare workflow companies. For instance, Phreesia, a patient intake and payment platform, reached a public market capitalization of over $1 billion by digitizing the front-end of the patient visit across multiple specialties [Phreesia IPO, 2019]. While CuraDia is earlier and more specialized, a scenario where it becomes the dominant data capture layer in North American urology clinics could support a valuation in the high hundreds of millions, based on capturing a portion of the administrative spend within a multi-billion dollar specialty care segment. This is a scenario-dependent outcome, not a forecast, but it illustrates the potential scale of solving a pervasive, high-friction problem for a lucrative medical field.

Partially corroborated -- The opportunity analysis is based on the company's stated product focus and market entry point, with a comparable outcome (Phreesia) cited from public markets. The growth scenarios are conditional constructs based on the company's platform language and founder background, not on confirmed commercial traction.

Sources

Open sources

1. [CuraDia, May 2026] CuraDia , The clinical operating system for urology | https://curadia.ca/

2. [Startupfest, July 2026] Startupfest Village Directory | https://www.startupfest.com/startupfest-village-directory

3. [Apple Podcasts] Talk With Claude | https://podcasts.apple.com/us/podcast/talk-with-claude/id1467300626

4. [Publisher] Patient-Reported Outcome Software Market Report | URL not provided in research

5. [Phreesia IPO, 2019] Phreesia Initial Public Offering | URL not provided in research